InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital started coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target for the company.

InspireMD Price Performance

InspireMD stock opened at $2.80 on Tuesday. The stock has a market capitalization of $83.13 million, a PE ratio of -3.73 and a beta of 0.88. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.80. The business has a 50 day simple moving average of $2.85 and a 200-day simple moving average of $2.76.

Institutional Trading of InspireMD

Several large investors have recently made changes to their positions in NSPR. Parkman Healthcare Partners LLC grew its holdings in InspireMD by 721.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock valued at $2,248,000 after buying an additional 750,635 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in InspireMD in the 4th quarter valued at $191,000. Northern Trust Corp grew its holdings in InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after buying an additional 18,233 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new position in shares of InspireMD in the 4th quarter valued at $47,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.